| Literature DB >> 33341484 |
Isidro García-Meniño1, Lorena Forcelledo2, Yaiza Rosete3, Emilio García-Prieto4, Dolores Escudero2, Javier Fernández5.
Abstract
The impact of secondary infections by multidrug-resistant bacteria in COVID-19- infected patients has yet to be evaluated. Here, we report the clinical and molecular features of an outbreak of seven patients carrying CTX-M-15- and OXA-48-producing Klebsiella pneumoniae belonging to ST326 during COVID-19 pandemic in an ICU in northern Spain. Those patients were admitted to beds close to each other, two of them developed ventilator-associated pneumonia (VAP), one exhibited primary bacteremia and the remaining four were considered to be colonized. None of them was colonized prior to admission to the ICU an all, except one of those who developed VAP, were discharged. Hydroxychloroquine and lopinavir/ritonavir were administered to all of them as COVID-19 therapy and additionally, three of them received tocilizumab and corticosteroids, respectively. Reusing of personal protective equipment due to its initial shortage, relaxation in infection control measures and negative-pressure air in ICU rooms recommended for the protection of health care workers (HCWs), could have contributed to this outbreak. Maximization of infection control measures is essential to avoid secondary infections by MDR bacteria in COVID-infected patients.Entities:
Keywords: COVID-19; ICU; K. pneumoniae; OXA-48; Secondary infections
Year: 2020 PMID: 33341484 PMCID: PMC7713590 DOI: 10.1016/j.jiph.2020.11.001
Source DB: PubMed Journal: J Infect Public Health ISSN: 1876-0341 Impact factor: 3.718
Clinical features of COVID-19 patients colonized/infected by OXA-48 producing Klebsiella pneumoniae.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | |
|---|---|---|---|---|---|---|---|
| Sex/Age | Male/66 | Male/67 | Male/76 | Male/69 | Female/71 | Male/54 | Male/66 |
| Comorbidities | None | Diabetes, Ischemic heart disease | Hypertension, Diabetes, Asthma, Epilepsy | None | Hypertension | SDRA-Influenza | Dilated |
| Type of interaction | Infection | Colonization | Infection | Infection | Colonization | Colonization | Colonization |
| Sample | Blood | Traqueal aspirate | Traqueal aspirate | Traqueal aspirate | Rectal swab | Rectal swab | Rectal swab |
| Type of infection | Primary bacteremia | VAP | VAP | ||||
| Prior | No | No | No | No | No | No | No |
| Days on general | 1 | 4 | 0 | 3 | 0 | 0 | 0 |
| Days from ICU admission to positive culture | 9 | 9 | 9 | 4 | 7 | 15 | 12 |
| Mechanical ventilation | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Previous antibiotics | Ceftriaxone, Azithromycin | Ceftriaxone, Piperacilin/Tazobactam | Ceftriaxone, Azithromycin, Piperacilin/Tazobactam, Vancomycin | Ceftriaxone, Azithromycin | Ceftriaxone | Ceftriaxone, Piperacilin/Tazobactam, Ceftazidime | Ceftriaxone, Ceftazidime, Meropenem |
| COVID treatment | HCQ, L/T, Corticoids | HCQ, L/T, Tocilizumab | HCQ, L/T, Corticoids, Tocilizumab | HCQ, L/T, Tocilizumab | HCQ, L/T | HCQ, L/T, Corticoids | HCQ, L/T |
| Outcome | Discharged | Discharged | Dead | Discharged | Discharged | Discharged | Discharged |
ICU, intensive care unit; VAP, ventilator associated pneumonia; L/R, lopinavir/ritonavir; HCQ, hydroxychloroquine.